News releases

The generic and biosimilar medicines industries will need to learn more about the Government of Canada’s approach to implementation, and consult with key stakeholders, to help ensure that a transition to this program would maximize the use of cost-saving generic and biosimilar medicines, while protecting Canada’s drug supply and domestic manufacturing capacity.

Toronto – October 12, 2023 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, welcomes the announcement by the Government of Prince Edward Island (PEI) that it is implementing a “switching” or transitioning policy to expand the use...

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by the Yukon Government that it is implementing a “switching” or transitioning policy to expand the use of biosimilar biologic medicines for its public drug programs.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, welcomes the announcement by the Government of Newfoundland and Labrador that it is implementing a “switching” or transitioning policy to expand the use of biosimilar biologic medicines for its public drug program.

Biosimilars Canada is pleased to announce the unanimous election of Mr. Mike Woolcock, Senior Vice President of the Apobiologix division of Apotex, as Chair of the Biosimilars Canada Board. Mr. Mike Casia, President and Managing Director of Organon Canada, has been unanimously elected as Vice-Chair of the Biosimilars Canada Board.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by Ontario Health Minister Sylvia Jones that the province will implement a “switching” or transitioning policy to expand the use of biosimilar biologic medicines for the Ontario Drug Benefit (ODB) program in 2023.